DETECTION AND SIGNIFICANCE OF OCCULT METASTASES IN NODE-NEGATIVE BREAST-CANCER

被引:200
作者
HAINSWORTH, PJ
TJANDRA, JJ
STILLWELL, RG
MACHET, D
HENDERSON, MA
RENNIE, GC
MCKENZIE, IFC
BENNETT, RC
机构
[1] UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA
[2] UNIV VICTORIA,DEPT SURG,VICTORIA V8W 2Y2,BC,CANADA
[3] ST VINCENTS HOSP,DEPT ANAT PATHOL,MELBOURNE,VIC,AUSTRALIA
关键词
D O I
10.1002/bjs.1800800417
中图分类号
R61 [外科手术学];
学科分类号
摘要
The clinical value of lymph node immunohistochemistry was assessed in 343 consecutive patients with apparently node-negative breast cancer using antimucin monoclonal antibodies BC2, BC3 and 3E1.2. Occult metastases were detected in 41 patients (12 per cent). Although most of these were micrometastatic (< 2 mm in diameter), larger or diffuse deposits were found in ten patients. Blind assessment of repeat haematoxylin and eosin stained sections detected metastases in ten of the 41 patients with occult metastases. After a median follow-up of 79 months, patients with occult metastases had a shorter time to disease recurrence (P < 0.05) but not to death. After adjustment for other prognostic factors, the presence of occult metastases in two or more nodes was the most significant predictor of both disease recurrence (P < 0.01) and death (P < 0.01). When the ten patients with positive haematoxylin and eosin sections were excluded from the analysis, the presence of occult metastases in two or more nodes was still associated with a reduced disease-free interval (P < 0.05) and survival (P < 0.05). Lymph node immunohistochemistry is a simple technique affording more accurate definition of nodal involvement than conventional methods.
引用
收藏
页码:459 / 463
页数:5
相关论文
共 32 条
[1]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[2]   THE IMMUNOHISTOCHEMICAL DETECTION OF LYMPH-NODE METASTASES FROM INFILTRATING LOBULAR CARCINOMA OF THE BREAST [J].
BUSSOLATI, G ;
GUGLIOTTA, P ;
MORRA, I ;
PIETRIBIASI, F ;
BERARDENGO, E .
BRITISH JOURNAL OF CANCER, 1986, 54 (04) :631-636
[3]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[4]  
2-H
[5]   A RANDOMIZED CLINICAL-TRIAL EVALUATING SEQUENTIAL METHOTREXATE AND FLUOROURACIL IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR-NEGATIVE TUMORS [J].
FISHER, B ;
REDMOND, C ;
DIMITROV, NV ;
BOWMAN, D ;
LEGAULTPOISSON, S ;
WICKERHAM, DL ;
WOLMARK, N ;
FISHER, ER ;
MARGOLESE, R ;
SUTHERLAND, C ;
GLASS, A ;
FOSTER, R ;
CAPLAN, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :473-478
[6]  
FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO
[7]  
2-3
[8]   A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484
[9]  
FISHER ER, 1978, CANCER, V42, P2025, DOI 10.1002/1097-0142(197810)42:4<2025::AID-CNCR2820420452>3.0.CO
[10]  
2-J